Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus Pembrolizumab and Carboplatin in Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07276399Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jun 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Survival and Objective Response Rate. Started Dec 2025; status: recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07276399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276399.